Medical testing company Quest Diagnostics says 11.9 million customers may have had their medical and financial information compromised due to a data breach at a third-party billing company. The ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Quest Diagnostics (DGX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...

Quest Diagnostics named Dr. Yuri Fesko, a seasoned health care executive and oncologist, its new senior vice president and chief medical officer. In a Dec. 20 press release announcing the appointment, ...

What To Know: While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP earnings per share guidance to a range of $8.58 to $8.66 from a ...

Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging ...

Quest Diagnostics Inc.’s DGX third-quarter 2025 adjusted earnings per share (EPS) of $2.60 beat the Zacks Consensus Estimate by 3.59%. The metric also exceeded the year-ago adjusted figure by 13%.

Epic will provide software to Quest Diagnostics under a new deal to improve digital connectivity with health systems and other providers. The EHR company, which has been expanding its laboratory ...

This company does not properly train their staff, nor do they hold any of their staff accountable for how they behave. The staff is consistently rude, unhelpful and actively obstructionist regardless ...